These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34847186)

  • 1. Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo.
    Izadi S; Jalali Javaran M; Rashidi Monfared S; Castilho A
    PLoS One; 2021; 16(11):e0260796. PubMed ID: 34847186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous expression, purification and single step efficient refolding of recombinant tissue plasminogen activator (Reteplase) from E. coli.
    Bhatt M; Masi HA; Patel A; Singh NK; Joshi C
    Protein Expr Purif; 2024 Sep; 221():106504. PubMed ID: 38782082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced clot lysis by a single point mutation in a reteplase variant.
    Chen S; Chen D; Liu Y; Xu Y; Lin H; Cheng Y; Li J; Meng C; Liang M; Yuan C; Huang M
    Br J Haematol; 2022 Feb; 196(4):1076-1085. PubMed ID: 34783361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Instability of Dimeric Fc-Fusions Expressed in Plants Can Be Solved by Monomeric Fc Technology.
    Gattinger P; Izadi S; Grünwald-Gruber C; Kallolimath S; Castilho A
    Front Plant Sci; 2021; 12():671728. PubMed ID: 34305971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion Expression and Fibrinolytic Activity of rPA/SP-B.
    Tang YS; Zhang XJ; Wang WN; Wang T; Cao WL; Zhang QH; Chen F
    Protein Pept Lett; 2021; 28(9):1033-1042. PubMed ID: 33645472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reteplase: Structure, Function, and Production.
    Mohammadi E; Seyedhosseini-Ghaheh H; Mahnam K; Jahanian-Najafabadi A; Mir Mohammad Sadeghi H
    Adv Biomed Res; 2019; 8():19. PubMed ID: 31016177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in clot lysis levels of reteplase and streptokinase following continuous wave ultrasound exposure, at ultrasound intensities following attenuation from the skull bone.
    Härdig BM; Carlson J; Roijer A
    BMC Cardiovasc Disord; 2008 Aug; 8():19. PubMed ID: 18727834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct action on the molecule is one of several mechanisms by which ultrasound enhances the fibrinolytic effects of reteplase.
    Härdig BM; Persson HW; Olsson SB
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):105-12. PubMed ID: 16479192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The production of improved tissue-type plasminogen activator in Escherichia coli.
    Mattes R
    Semin Thromb Hemost; 2001 Aug; 27(4):325-36. PubMed ID: 11547355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioevaluation of
    Yang W; Wang W; Ma Y; Yang Q; Li P; Du S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic agents in development.
    Verstraete M; Lijnen HR; Collen D
    Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of reteplase with heparin. A comparison between reteplase and alteplase.
    Rijken DC; Jie AF
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):561-6. PubMed ID: 8874867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotechnological production of recombinant tissue plasminogen activator protein (reteplase) from transplastomic tobacco cell cultures.
    Hidalgo D; Abdoli-Nasab M; Jalali-Javaran M; Bru-Martínez R; Cusidó RM; Corchete P; Palazon J
    Plant Physiol Biochem; 2017 Sep; 118():130-137. PubMed ID: 28633085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage.
    Keric N; Döbel M; Krenzlin H; Kurz E; Tanyildizi Y; Heimann A; König J; Kempski O; Ringel F; Masomi-Bornwasser J
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105073. PubMed ID: 32807475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
    Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
    Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Characterization of Plasmin-Independent Thrombolytic Enzymes.
    Hassan MM; Sharmin S; Kim HJ; Hong ST
    Circ Res; 2021 Feb; 128(3):386-400. PubMed ID: 33292062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.